|
CISS
|
TOAST
|
Total
|
|---|
|
LAA
|
CE
|
SAO
|
SOE
|
SUE
|
|---|
|
LAA
|
78
|
3
|
30
|
0
|
38
|
149
|
|
LAA-A
|
0
|
0
|
0
|
0
|
0
|
0
|
|
LAA-1
|
37
|
0
|
24
|
0
|
8
|
69
|
|
LAA-2
|
20
|
2
|
4
|
0
|
15
|
41
|
|
LAA-3
|
4
|
0
|
0
|
0
|
5
|
9
|
|
LAA-4
|
17
|
3
|
2
|
0
|
10
|
30
|
|
CS
|
0
|
10
|
1
|
0
|
2
|
13
|
|
PAD
|
9
|
1
|
96
|
1
|
25
|
132
|
|
OE
|
0
|
0
|
0
|
6
|
0
|
6
|
|
UE
|
2
|
1
|
0
|
0
|
17
|
20
|
|
Total
|
89
|
15
|
127
|
7
|
82
|
320
|
-
CISS Chinese ischemic stroke subclassfication, TOAST trial of Org 10172 in acute stroke treatment, LAA large artery atherosclerosis, LAA-A aortic arch atherosclerosis, LAA-1 parent artery (plaque or thrombus) occluding penetrating artery, LAA-2 artery-to-artery embolism, LAA-3 hypoperfusion/impaired emboli clearance, LAA-4 hypoperfusion/impaired emboli clearance, CS cardiogenic stroke, PAD penetrating artery disease, OE other etiologies, UE undetermined etiology, CE cardioembolism, SAO small-artery occlusion, SOE stroke of other etiologies, SUE stroke of undetermined etiology
-
k = 0.487
